•  Development of new aerosol metrology tools: creation of 3 predictive anatomical models of the nasal cavity for predicting nasal aerosol deposition (Le Guellec et al. Pharm Res. 2014). These models are central to new international collaborations (University of Parma, Italy)

  •  Development of the first prototype device for inhaling an antibody into the distal lung, for the treatment of pulmonary intoxication with ricin (Respaud et al. J Control Release. 2016 – selected for the “cover story” of issue 234). Television feature for Magazine de la Santé (aired on 05/09/2016)


  •  Establishment of a new animal model, in non-human primates (NHP), to determine the pulmonary pharmacokinetics (PK) of inhaled antibodies – within the framework of a partnership with Sanofi-Genzyme (1st prize in the Innovative Supportive Technology category of the Sanofi Global R&D Sciences Awards, 2015)

  •  3 patents under license or in exploitation relating to aerosol delivery medical devices (Protec’som, Aptar Pharma and Nemera). 1 additional patent was filed and 2 invention declarations received a favourable assessment.

  • Strengthening of the team by the inclusion of 3 new university hospital staff members (since recognition of the team by INSERM in 2015) and one post-doctoral researcher.

  • Organisation of the first international symposium (31/03 and 01/04/2016, in Tours) on “therapeutic antibodies and respiratory diseases: problems and prospects” (TMARD) as part of the MAbImprove LabEx, research group n°3260 “Antibodies and targeted therapy” and the ARD2020 regional programme “Biodrugs” (Centre-Val-de-Loire Region) – about 150 participants from academic and industrial circles (Desoubeaux et al. MAbs. 2016. 8(6):999-1009).

  •  Election of P. Diot as Dean of the Tours Faculty of Medicine in 2014.